MONDAY, Sept. 8 (HealthDay News) -- In patients with diabetes, treatment with a once-weekly form of exenatide may result in better glycemic control than twice-a-day exenatide, according to the results of a study published online Sept. 8 in The Lancet.
Daniel J. Drucker, M.D., of the University of Toronto in Ontario, Canada, and colleagues randomly assigned 295 patients to receive either a long-acting release formulation of exenatide administered once weekly or standard exenatide administered twice a day and followed them for 30 weeks.
Compared to the twice-a-day group, the researchers found that the once-weekly group had a significantly greater mean change in hemoglobin A1c (-1.9 versus -1.5). They also found that a higher proportion of once-weekly patients achieved hemoglobin A1c levels of 7 percent or lower (77 percent versus 61 percent).
"In view of the complexity of current diabetes treatment options requiring once or twice daily administration of therapeutic agents, the significant improvement in HbA1c in association with weight loss observed with a once-weekly formulation of exenatide suggests that continuous GLP-1R activation offers a promising treatment option for the management of type 2 diabetes," the authors write.
This study was funded by Amylin Pharmaceuticals, Inc., and Eli Lilly and Company. Several of the study authors report financial relationships with the pharmaceutical industry.
Abstract
Full Text (subscription or payment may be required)
Editorial
